Related Experiment Video

Updated: Jun 10, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

MUC1 immunotherapy

Richard E Beatson1, Joyce Taylor-Papadimitriou, Joy M Burchell

  • 1Breast Cancer Biology Group, King's College London, Guy's Hospital, London SE1 9RT, UK.

Immunotherapy
|July 20, 2010
PubMed

Insights

MUC1 protein

Area of Science:

  • Oncology
  • Immunology
  • Glycobiology

Background:

  • MUC1 is overexpressed and aberrantly glycosylated in many cancers.
  • This aberrant MUC1 is a promising target for cancer immunotherapy.

Purpose of the Study:

  • To review MUC1-targeted immunotherapies for adenocarcinomas.
  • To discuss challenges and solutions in MUC1 immunotherapy.
  • To predict future research directions for MUC1 immunotherapy.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of current MUC1-targeted immunotherapeutic strategies.
  • Discussion of challenges and potential solutions.

Main Results:

  • Several MUC1-based immunotherapeutic approaches are under investigation.
  • Challenges include MUC1 heterogeneity and immune evasion.
  • Potential solutions involve combination therapies and novel delivery systems.

Conclusions:

  • MUC1 immunotherapy holds significant promise for treating adenocarcinomas.
  • Overcoming current challenges is crucial for clinical success.
  • Future research will likely focus on refining MUC1 targeting and enhancing immune responses.

More Related Videos

Mucin Agarose Gel Electrophoresis: Western Blotting for High-molecular-weight Glycoproteins09:24

Mucin Agarose Gel Electrophoresis: Western Blotting for High-molecular-weight Glycoproteins

Published on: June 14, 2016

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining. Bicarbonate,...
Mucosal Barrier of the Stomach01:25

Mucosal Barrier of the Stomach

The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...